Allspring Global Investments’s ProKidney PROK Stock Holding History

Allspring Global Investments’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-71	Closed	-$325	–	2631
2023 Q3	$325	Buy	+71	New	+$680	﹤0.01%	2764

Other funds holding PROK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Brown University Providence, Rhode Island $102M AUM 26.79% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Allspring Global Investments's PROK Position: Q4 2023 in Review

Allspring Global Investments sold out of ProKidney (PROK) in Q4 2023, closing a stake of 71 shares — an estimated $325 sold.

Allspring Global Investments first reported a position in PROK in Q3 2023 and held it in 1 quarter. The position peaked at $325 in Q3 2023. 61 funds tracked by Wall St. Rank hold PROK as of Q4 2023.

Allspring Global Investments reported no remaining ProKidney position as of Q4 2023 after selling out during the quarter.
Allspring Global Investments sold 71 ProKidney shares in Q4 2023, an estimated $325.
Allspring Global Investments first reported a position in ProKidney in Q3 2023 and held it in 1 quarter.
Allspring Global Investments's ProKidney position peaked at $325 in Q3 2023.
61 funds tracked by Wall St. Rank held ProKidney as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.